James Bianco, Chief Executive Officer and President of CTI BioPharma Corp (NASDAQ:CTIC), unloaded 50,000 shares of Common Stock on Friday, paying a price of $2.84 per share. This is Bianco’s second stock sale in June, as the CEO disposed of 55,000 shares of Common Stock for $2.99 per share, earlier in the month. Louis Bianco, Executive Vice President, Finance and Administration at the $428.5 million market cap biopharmaceutical firm, has also regularly been unloading company shares over the past month. However, the Executive VP’s most recent sale was of much smaller content, disposing of 1,800 shares for $3.00 per share.
On another note, this quarter showed many new shareholder positions at CTI BioPharma. While Ken Griffin’s hedge fund, Citadel Investment Group, remains one of the majority shareholders, with 619,473 shares, worth $2.1 million, Adage Capital Management has entered a very strong shareholder position this quarter. Owning 1 million shares, for a value of $3.4 million, Phill Gross and Robert Atchinson’s hedge fund is now the largest shareholder at CTI.